Michael Kishbauch

Independent Director
Michael Kishbauch has served as a member of our board of directors since April 2016. He has served as a director of Achillion Pharmaceuticals, Inc., or Achillion, a biotechnology company, since July 2004. Mr. Kisbauch has also served as a director of Progenics Pharmaceuticals, Inc., a biopharmaceutical company, since September 2013 and of TetraLogic Pharmaceuticals Corporation, a biopharmaceutical company, since November 2014. Mr. Kishbauch previously served as President and Chief Executive Officer of Achillion from July 2004 until his retirement in September 2013. Prior to that, he founded and served as President and Chief Executive Officer of OraPharma, Inc., a commercial-stage pharmaceutical company focused on oral health care that was acquired by Johnson & Johnson in 2003, from 1996 to 2004. Mr. Kishbauch also held senior management positions with MedImmune, Inc., a biotechnology company, from 1992 to 1995. Mr. Kishbauch holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University.
Financial Expert